CSTONE PHARMA-B (02616) Receives Further Investment from GIC! Stake Rises to 8.06%

Stock News2025-12-30

According to the latest data from the Hong Kong Stock Exchange, GIC Private Limited increased its stake in CSTONE PHARMA-B (02616) by 904,500 shares on December 23, at a price of HK$5.8476 per share, with a total transaction value of approximately HK$5.2892 million. Following this acquisition, GIC's total shareholding has risen to approximately 119 million shares, representing a stake of 8.06%. Notably, as a top-tier international long-term capital investor, GIC's optimistic outlook on CSTONE PHARMA is clear and demonstrates a consistent pattern. Reviewing the trajectory of these acquisitions, since GIC first disclosed a 5.49% stake in CSTONE PHARMA on August 18 this year, its buying activity has been continuous: following disclosures of further purchases on October 13 and November 10, its stake increased to 7.11%, culminating in the latest disclosed stake of 8.06%. Over a span of just over four months, from August 18 to the latest disclosure date of December 23, the stake has steadily grown, with cumulative purchases exceeding 38 million shares, which fully underscores the high level of recognition from this international sovereign wealth fund regarding the company's core value and long-term development potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153603904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 08:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153603904","market":"hk","top_or_hot":-1,"title":"CSTONE PHARMA-B (02616) Receives Further Investment from GIC! Stake Rises to 8.06%","media":"Stock News","content":"<p>According to the latest data from the Hong Kong Stock Exchange, GIC Private Limited increased its stake in CSTONE PHARMA-B (02616) by 904,500 shares on December 23, at a price of HK$5.8476 per share, with a total transaction value of approximately HK$5.2892 million.\nFollowing this acquisition, GIC's total shareholding has risen to approximately 119 million shares, representing a stake of 8.06%.\nNotably, as a top-tier international long-term capital investor, GIC's optimistic outlook on CSTONE PHARMA is clear and demonstrates a consistent pattern.\nReviewing the trajectory of these acquisitions, since GIC first disclosed a 5.49% stake in CSTONE PHARMA on August 18 this year, its buying activity has been continuous: following disclosures of further purchases on October 13 and November 10, its stake increased to 7.11%, culminating in the latest disclosed stake of 8.06%.\nOver a span of just over four months, from August 18 to the latest disclosure date of December 23, the stake has steadily grown, with cumulative purchases exceeding 38 million shares, which fully underscores the high level of recognition from this international sovereign wealth fund regarding the company's core value and long-term development potential.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSTONE PHARMA-B (02616) Receives Further Investment from GIC! Stake Rises to 8.06%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSTONE PHARMA-B (02616) Receives Further Investment from GIC! Stake Rises to 8.06%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-30 08:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the latest data from the Hong Kong Stock Exchange, GIC Private Limited increased its stake in CSTONE PHARMA-B (02616) by 904,500 shares on December 23, at a price of HK$5.8476 per share, with a total transaction value of approximately HK$5.2892 million.\nFollowing this acquisition, GIC's total shareholding has risen to approximately 119 million shares, representing a stake of 8.06%.\nNotably, as a top-tier international long-term capital investor, GIC's optimistic outlook on CSTONE PHARMA is clear and demonstrates a consistent pattern.\nReviewing the trajectory of these acquisitions, since GIC first disclosed a 5.49% stake in CSTONE PHARMA on August 18 this year, its buying activity has been continuous: following disclosures of further purchases on October 13 and November 10, its stake increased to 7.11%, culminating in the latest disclosed stake of 8.06%.\nOver a span of just over four months, from August 18 to the latest disclosure date of December 23, the stake has steadily grown, with cumulative purchases exceeding 38 million shares, which fully underscores the high level of recognition from this international sovereign wealth fund regarding the company's core value and long-term development potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1153603904","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153603904","pubTimestamp":1767056059,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to the latest data from the Hong Kong Stock Exchange, GIC Private Limited increased its stake in CSTONE PHARMA-B (02616) by 904,500 shares on December 23, at a price of HK$5.8476 per share,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","GIC":"Global Industry Company","BK4104":"贸易公司与经销商","02616":"基石药业-B"},"translate_title":"基石药业-B(02616)获GIC进一步投资！持股增至8.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1,"GIC":1},"content_text":"According to the latest data from the Hong Kong Stock Exchange, GIC Private Limited increased its stake in CSTONE PHARMA-B (02616) by 904,500 shares on December 23, at a price of HK$5.8476 per share, with a total transaction value of approximately HK$5.2892 million.\nFollowing this acquisition, GIC's total shareholding has risen to approximately 119 million shares, representing a stake of 8.06%.\nNotably, as a top-tier international long-term capital investor, GIC's optimistic outlook on CSTONE PHARMA is clear and demonstrates a consistent pattern.\nReviewing the trajectory of these acquisitions, since GIC first disclosed a 5.49% stake in CSTONE PHARMA on August 18 this year, its buying activity has been continuous: following disclosures of further purchases on October 13 and November 10, its stake increased to 7.11%, culminating in the latest disclosed stake of 8.06%.\nOver a span of just over four months, from August 18 to the latest disclosure date of December 23, the stake has steadily grown, with cumulative purchases exceeding 38 million shares, which fully underscores the high level of recognition from this international sovereign wealth fund regarding the company's core value and long-term development potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153603904","isCrawlerRequest":true}